234080 — JW Life Science Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeSmall CapSuper Stock

Annual income statement for JW Life Science, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	183,521	169,817	188,931	206,860	222,478
Cost of Revenue
Gross Profit	59,497	49,157	48,121	52,393	57,508
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	151,253	141,315	161,842	176,009	186,620
Operating Profit	32,268	28,502	27,089	30,851	35,858
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	22,740	18,287	20,782	33,708	59,027
Provision for Income Taxes
Net Income After Taxes	17,300	12,914	14,961	28,144	43,988
Net Income Before Extraordinary Items
Net Income	17,300	12,914	14,961	28,144	43,988
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	17,300	12,914	14,961	28,144	43,988
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1,438	841	967	1,827	2,841
Dividends per Share